MAVS and hepatocellular carcinoma: For example, the palmitoylation and ubiquitination of MAVS jointly regulate antitumor immunity[70]; the palmitoylation‐mediated ubiquitination of PHF2 remodels lipid metabolism in hepatocellular carcinoma[71]; and the palmitoylation of FASN competes with ubiquitination to promote hepatocellular carcinoma progression.[72] Our findings further elucidate the crosstalk between palmitoylation and ubiquitination in prostate cancer.